Bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21

• Type: Article in International Scientific Journal
• Date: 2005

Authors

Slovin, SF (Author) Other; Ragupathi, G (Author) Other; Fernandez, C (Author) Other; Jefferson, MP (Author) Other; Diani, M (Author) Other; Wilton, AS (Author) Other; Powell, S (Author) Other; Spassova, M (Author) Other; Celso Reis (Author) FMUP; Clausen, H (Author) Other; Danishefsky, S (Author) Other; Livingston, P (Author) Other; Scher, HI (Author) Other

Journal

Title: Vaccine

Vol. 23

Pages: 3114-3122

ISSN: 0264-410X

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 53 Citations

Other information

Authenticus ID: P-00G-9E0

DOI: 10.1016/j.vaccines.2005.01.072

Abstract (EN): GPI-0100 is a semi-synthetic saponin with modifications designed to augment stability and diminish toxicity. Two batches of GPI-0100 (the second with higher purity) were tested with doses ranging between 100 and 5000 mu g in groups of five treated prostate cancer patients who had no evidence of disease except for rising PSA levels. GPI-0100 was mixed with a bivalent vaccine containing the glycolipid Globo H and the glycosylated mucin MUC2 conjugated to keyhole limpet hemocyanin (KLH). All doses were well tolerated and antibody titers against Globo H and MUC-2 escalated with the increasing dose levels. At the 5000 p,g dose level in this patient population, toxicity remained minimal with only occasional grade II local toxicity at vaccination sites and occasional sporadic grade I elevations in ALT. Compared with a subsequent trial with the same bivalent vaccine plus QS-21 at the maximal tolerated dose of 100 mu g, the 5000 mu g dose of GPI-0100 produced comparable antibody titers.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 9